Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients . The study was conducted in accordance with the Good Practice for Quality Control of Clinical Trials for Pharmaceutical Products (GCP). Approximately 20 subjects will be enrolled to evaluate the efficacy and safety of RC48 (2.0 mg/kg intravenously every 3 weeks) combined with Tislelizumab (200mg intravenously every 3 weeks).
Upper Urinary Tract Urothelial Carcinoma|Kidney Preservation|HER-2 ADC|PD-1antibody
DRUG: RC48 Combined With Tislelizumab
kidney-intact event-free survival (KI-EFS), Event-free survival is the time from the beginning of enrollment to the occurrence of any event, including death, disease progression, change of therapy regimen, and occurrence of fatal or intolerable side effects, up to 1 year
clinical complete response, The rate of CCR is defined by negative ureteroscope, urine cytology, and negative imaging, 3 month after surgery|Metastasis-Free Survival, MFS, Metastasis-Free Survival is the time from the beginning of enrollment to the occurrence of metastasis, up to 2 year|the proportion of adverse events, the proportion of adverse events occurring during the treatment period and subsequent follow-up, up to 2 year|the proportion of RUN, The proportion of patients undergoing radical surgery for UTUC (upper tract urothelial carcinoma) after enrollment., up to 2 year
This is a prospective, open, multiple-center clinical study of renal preservation therapy in high-risk upper urinary tract urothelial carcinoma patients . The study was conducted in accordance with the Good Practice for Quality Control of Clinical Trials for Pharmaceutical Products (GCP). Approximately 20 subjects will be enrolled to evaluate the efficacy and safety of RC48 (2.0 mg/kg intravenously every 3 weeks) combined with Tislelizumab (200mg intravenously every 3 weeks).